TSIDS02a:	Subject Disposition by [Subgroup]; [Randomized/Enrolled] Analysis Set (Study jjcs - core)							
 	Active Study Agent 	Active Study Agent 	 	 	Risk Difference (%) 95% CI 	Risk Difference (%) 95% CI 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Total 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
  	N=84 	N=84 	N=86 	N=254 	  	  	
Race: American Indian or Alaska Native 	7 	13 	6 	26 	 	 	
Analysis set: 	 	 	 	 	 	 	
Full 	7 (100.0%) 	13 (100.0%) 	6 (100.0%) 	26 (100.0%) 	 	 	
Safety 	5 (71.4%) 	10 (76.9%) 	3 (50.0%) 	18 (69.2%) 	 	 	
Per protocol 	5 (71.4%) 	10 (76.9%) 	3 (50.0%) 	18 (69.2%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	2 (28.6%) 	0 	0 	2 (7.7%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	1 (14.3%) 	3 (23.1%) 	3 (50.0%) 	7 (26.9%) 	-35.7 (-83.4, 12.0) 	-26.9 (-73.0, 19.2) 	
Discontinued treatment 	5 (71.4%) 	7 (53.8%) 	1 (16.7%) 	13 (50.0%) 	54.8 (9.9, 99.6) 	37.2 (-3.1, 77.5) 	
Other 	5 (71.4%) 	7 (53.8%) 	1 (16.7%) 	13 (50.0%) 	54.8 (9.9, 99.6) 	37.2 (-3.1, 77.5) 	
 	  	  	  	  	  	  	
Completed study 	2 (28.6%) 	3 (23.1%) 	4 (66.7%) 	9 (34.6%) 	-38.1 (-88.5, 12.3) 	-43.6 (-87.7, 0.5) 	
Discontinued study 	3 (42.9%) 	10 (76.9%) 	2 (33.3%) 	15 (57.7%) 	9.5 (-43.1, 62.1) 	43.6 (-0.5, 87.7) 	
Other 	3 (42.9%) 	10 (76.9%) 	2 (33.3%) 	15 (57.7%) 	9.5 (-43.1, 62.1) 	43.6 (-0.5, 87.7) 	
 	 	 	 	 	 	 	
Race: Asian 	11 	11 	7 	29 	 	 	
Analysis set: 	 	 	 	 	 	 	
Full 	11 (100.0%) 	11 (100.0%) 	7 (100.0%) 	29 (100.0%) 	 	 	
Safety 	11 (100.0%) 	8 (72.7%) 	5 (71.4%) 	24 (82.8%) 	 	 	
Per protocol 	11 (100.0%) 	8 (72.7%) 	5 (71.4%) 	24 (82.8%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	1 (9.1%) 	2 (18.2%) 	2 (28.6%) 	5 (17.2%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	3 (27.3%) 	4 (36.4%) 	2 (28.6%) 	9 (31.0%) 	-1.3 (-43.9, 41.3) 	7.8 (-36.1, 51.7) 	
Discontinued treatment 	7 (63.6%) 	6 (54.5%) 	3 (42.9%) 	16 (55.2%) 	20.8 (-25.6, 67.2) 	11.7 (-35.3, 58.7) 	
Other 	7 (63.6%) 	6 (54.5%) 	3 (42.9%) 	16 (55.2%) 	20.8 (-25.6, 67.2) 	11.7 (-35.3, 58.7) 	
 	  	  	  	  	  	  	
Completed study 	3 (27.3%) 	3 (27.3%) 	2 (28.6%) 	8 (27.6%) 	-1.3 (-43.9, 41.3) 	-1.3 (-43.9, 41.3) 	
Discontinued study 	7 (63.6%) 	6 (54.5%) 	3 (42.9%) 	16 (55.2%) 	20.8 (-25.6, 67.2) 	11.7 (-35.3, 58.7) 	
Other 	7 (63.6%) 	6 (54.5%) 	3 (42.9%) 	16 (55.2%) 	20.8 (-25.6, 67.2) 	11.7 (-35.3, 58.7) 	
 	 	 	 	 	 	 	
Race: Black or African American 	7 	10 	10 	27 	 	 	
Analysis set: 	 	 	 	 	 	 	
Full 	7 (100.0%) 	10 (100.0%) 	10 (100.0%) 	27 (100.0%) 	 	 	
Safety 	5 (71.4%) 	9 (90.0%) 	7 (70.0%) 	21 (77.8%) 	 	 	
Per protocol 	5 (71.4%) 	9 (90.0%) 	7 (70.0%) 	21 (77.8%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	4 (57.1%) 	0 	3 (30.0%) 	7 (25.9%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	2 (28.6%) 	2 (20.0%) 	6 (60.0%) 	10 (37.0%) 	-31.4 (-76.6, 13.8) 	-40.0 (-79.2, -0.8) 	
Discontinued treatment 	4 (57.1%) 	6 (60.0%) 	3 (30.0%) 	13 (48.1%) 	27.1 (-19.2, 73.5) 	30.0 (-11.6, 71.6) 	
Other 	4 (57.1%) 	6 (60.0%) 	3 (30.0%) 	13 (48.1%) 	27.1 (-19.2, 73.5) 	30.0 (-11.6, 71.6) 	
 	  	  	  	  	  	  	
Completed study 	2 (28.6%) 	3 (30.0%) 	3 (30.0%) 	8 (29.6%) 	-1.4 (-45.3, 42.5) 	0.0 (-40.2, 40.2) 	
Discontinued study 	1 (14.3%) 	7 (70.0%) 	4 (40.0%) 	12 (44.4%) 	-25.7 (-65.6, 14.2) 	30.0 (-11.6, 71.6) 	
Other 	1 (14.3%) 	7 (70.0%) 	4 (40.0%) 	12 (44.4%) 	-25.7 (-65.6, 14.2) 	30.0 (-11.6, 71.6) 	
 	 	 	 	 	 	 	
Race: Multiple 	12 	9 	8 	29 	 	 	
Analysis set: 	 	 	 	 	 	 	
Full 	12 (100.0%) 	9 (100.0%) 	8 (100.0%) 	29 (100.0%) 	 	 	
Safety 	11 (91.7%) 	7 (77.8%) 	5 (62.5%) 	23 (79.3%) 	 	 	
Per protocol 	11 (91.7%) 	7 (77.8%) 	5 (62.5%) 	23 (79.3%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	2 (16.7%) 	3 (33.3%) 	1 (12.5%) 	6 (20.7%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	2 (16.7%) 	3 (33.3%) 	4 (50.0%) 	9 (31.0%) 	-33.3 (-73.9, 7.2) 	-16.7 (-63.0, 29.7) 	
Discontinued treatment 	7 (58.3%) 	3 (33.3%) 	2 (25.0%) 	12 (41.4%) 	33.3 (-7.6, 74.3) 	8.3 (-34.7, 51.3) 	
Other 	7 (58.3%) 	3 (33.3%) 	2 (25.0%) 	12 (41.4%) 	33.3 (-7.6, 74.3) 	8.3 (-34.7, 51.3) 	
 	  	  	  	  	  	  	
Completed study 	4 (33.3%) 	3 (33.3%) 	4 (50.0%) 	11 (37.9%) 	-16.7 (-60.4, 27.1) 	-16.7 (-63.0, 29.7) 	
Discontinued study 	6 (50.0%) 	3 (33.3%) 	3 (37.5%) 	12 (41.4%) 	12.5 (-31.4, 56.4) 	-4.2 (-49.7, 41.4) 	
Other 	6 (50.0%) 	3 (33.3%) 	3 (37.5%) 	12 (41.4%) 	12.5 (-31.4, 56.4) 	-4.2 (-49.7, 41.4) 	
 	 	 	 	 	 	 	
Race: Native Hawaiian or other Pacific Islander 	10 	7 	8 	25 	 	 	
Analysis set: 	 	 	 	 	 	 	
Full 	10 (100.0%) 	7 (100.0%) 	8 (100.0%) 	25 (100.0%) 	 	 	
Safety 	8 (80.0%) 	4 (57.1%) 	5 (62.5%) 	17 (68.0%) 	 	 	
Per protocol 	8 (80.0%) 	4 (57.1%) 	5 (62.5%) 	17 (68.0%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	3 (30.0%) 	1 (14.3%) 	2 (25.0%) 	6 (24.0%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	1 (10.0%) 	1 (14.3%) 	4 (50.0%) 	6 (24.0%) 	-40.0 (-79.3, -0.7) 	-35.7 (-79.0, 7.6) 	
Discontinued treatment 	6 (60.0%) 	5 (71.4%) 	3 (37.5%) 	14 (56.0%) 	22.5 (-22.7, 67.7) 	33.9 (-13.5, 81.3) 	
Other 	6 (60.0%) 	5 (71.4%) 	3 (37.5%) 	14 (56.0%) 	22.5 (-22.7, 67.7) 	33.9 (-13.5, 81.3) 	
 	  	  	  	  	  	  	
Completed study 	2 (20.0%) 	1 (14.3%) 	3 (37.5%) 	6 (24.0%) 	-17.5 (-59.2, 24.2) 	-23.2 (-65.6, 19.2) 	
Discontinued study 	5 (50.0%) 	5 (71.4%) 	3 (37.5%) 	13 (52.0%) 	12.5 (-33.2, 58.2) 	33.9 (-13.5, 81.3) 	
Other 	5 (50.0%) 	5 (71.4%) 	3 (37.5%) 	13 (52.0%) 	12.5 (-33.2, 58.2) 	33.9 (-13.5, 81.3) 	
 	 	 	 	 	 	 	
Race: Not reported 	11 	7 	11 	29 	 	 	
Analysis set: 	 	 	 	 	 	 	
Full 	11 (100.0%) 	7 (100.0%) 	11 (100.0%) 	29 (100.0%) 	 	 	
Safety 	7 (63.6%) 	5 (71.4%) 	9 (81.8%) 	21 (72.4%) 	 	 	
Per protocol 	7 (63.6%) 	5 (71.4%) 	9 (81.8%) 	21 (72.4%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	2 (18.2%) 	1 (14.3%) 	2 (18.2%) 	5 (17.2%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	3 (27.3%) 	1 (14.3%) 	6 (54.5%) 	10 (34.5%) 	-27.3 (-66.8, 12.2) 	-40.3 (-79.5, -1.0) 	
Discontinued treatment 	7 (63.6%) 	3 (42.9%) 	2 (18.2%) 	12 (41.4%) 	45.5 (9.0, 81.9) 	24.7 (-18.5, 67.8) 	
Other 	7 (63.6%) 	3 (42.9%) 	2 (18.2%) 	12 (41.4%) 	45.5 (9.0, 81.9) 	24.7 (-18.5, 67.8) 	
 	  	  	  	  	  	  	
Completed study 	2 (18.2%) 	2 (28.6%) 	7 (63.6%) 	11 (37.9%) 	-45.5 (-81.9, -9.0) 	-35.1 (-79.0, 8.8) 	
Discontinued study 	7 (63.6%) 	4 (57.1%) 	2 (18.2%) 	13 (44.8%) 	45.5 (9.0, 81.9) 	39.0 (-4.2, 82.1) 	
Other 	7 (63.6%) 	4 (57.1%) 	2 (18.2%) 	13 (44.8%) 	45.5 (9.0, 81.9) 	39.0 (-4.2, 82.1) 	
 	 	 	 	 	 	 	
Race: Other 	5 	11 	16 	32 	 	 	
Analysis set: 	 	 	 	 	 	 	
Full 	5 (100.0%) 	11 (100.0%) 	16 (100.0%) 	32 (100.0%) 	 	 	
Safety 	1 (20.0%) 	8 (72.7%) 	10 (62.5%) 	19 (59.4%) 	 	 	
Per protocol 	1 (20.0%) 	8 (72.7%) 	10 (62.5%) 	19 (59.4%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	1 (20.0%) 	2 (18.2%) 	1 (6.2%) 	4 (12.5%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	3 (60.0%) 	4 (36.4%) 	8 (50.0%) 	15 (46.9%) 	10.0 (-39.4, 59.4) 	-13.6 (-51.2, 23.9) 	
Discontinued treatment 	2 (40.0%) 	5 (45.5%) 	5 (31.2%) 	12 (37.5%) 	8.8 (-39.8, 57.3) 	14.2 (-23.0, 51.4) 	
Other 	2 (40.0%) 	5 (45.5%) 	5 (31.2%) 	12 (37.5%) 	8.8 (-39.8, 57.3) 	14.2 (-23.0, 51.4) 	
 	  	  	  	  	  	  	
Completed study 	2 (40.0%) 	4 (36.4%) 	10 (62.5%) 	16 (50.0%) 	-22.5 (-71.6, 26.6) 	-26.1 (-63.2, 10.9) 	
Discontinued study 	2 (40.0%) 	5 (45.5%) 	5 (31.2%) 	12 (37.5%) 	8.8 (-39.8, 57.3) 	14.2 (-23.0, 51.4) 	
Other 	2 (40.0%) 	5 (45.5%) 	5 (31.2%) 	12 (37.5%) 	8.8 (-39.8, 57.3) 	14.2 (-23.0, 51.4) 	
 	 	 	 	 	 	 	
Race: Unknown 	10 	6 	11 	27 	 	 	
Analysis set: 	 	 	 	 	 	 	
Full 	10 (100.0%) 	6 (100.0%) 	11 (100.0%) 	27 (100.0%) 	 	 	
Safety 	7 (70.0%) 	4 (66.7%) 	8 (72.7%) 	19 (70.4%) 	 	 	
Per protocol 	7 (70.0%) 	4 (66.7%) 	8 (72.7%) 	19 (70.4%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	0 	3 (50.0%) 	1 (9.1%) 	4 (14.8%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	2 (20.0%) 	2 (33.3%) 	9 (81.8%) 	13 (48.1%) 	-61.8 (-95.5, -28.1) 	-48.5 (-92.6, -4.4) 	
Discontinued treatment 	6 (60.0%) 	1 (16.7%) 	2 (18.2%) 	9 (33.3%) 	41.8 (3.9, 79.8) 	-1.5 (-39.0, 36.0) 	
Other 	6 (60.0%) 	1 (16.7%) 	2 (18.2%) 	9 (33.3%) 	41.8 (3.9, 79.8) 	-1.5 (-39.0, 36.0) 	
 	  	  	  	  	  	  	
Completed study 	3 (30.0%) 	2 (33.3%) 	8 (72.7%) 	13 (48.1%) 	-42.7 (-81.4, -4.0) 	-39.4 (-85.4, 6.6) 	
Discontinued study 	7 (70.0%) 	1 (16.7%) 	2 (18.2%) 	10 (37.0%) 	51.8 (15.4, 88.2) 	-1.5 (-39.0, 36.0) 	
Other 	7 (70.0%) 	1 (16.7%) 	2 (18.2%) 	10 (37.0%) 	51.8 (15.4, 88.2) 	-1.5 (-39.0, 36.0) 	
 	 	 	 	 	 	 	
Race: White 	11 	10 	9 	30 	 	 	
Analysis set: 	 	 	 	 	 	 	
Full 	11 (100.0%) 	10 (100.0%) 	9 (100.0%) 	30 (100.0%) 	 	 	
Safety 	9 (81.8%) 	7 (70.0%) 	7 (77.8%) 	23 (76.7%) 	 	 	
Per protocol 	9 (81.8%) 	7 (70.0%) 	7 (77.8%) 	23 (76.7%) 	 	 	
 	  	  	  	  	  	  	
Subjects ongoing 	3 (27.3%) 	3 (30.0%) 	2 (22.2%) 	8 (26.7%) 	 	 	
 	  	  	  	  	  	  	
Completed treatment 	2 (18.2%) 	1 (10.0%) 	7 (77.8%) 	10 (33.3%) 	-59.6 (-95.1, -24.1) 	-67.8 (-100.0, -34.9) 	
Discontinued treatment 	5 (45.5%) 	7 (70.0%) 	1 (11.1%) 	13 (43.3%) 	34.3 (-1.5, 70.2) 	58.9 (23.8, 93.9) 	
Other 	5 (45.5%) 	7 (70.0%) 	1 (11.1%) 	13 (43.3%) 	34.3 (-1.5, 70.2) 	58.9 (23.8, 93.9) 	
 	  	  	  	  	  	  	
Completed study 	2 (18.2%) 	0 	7 (77.8%) 	9 (30.0%) 	-59.6 (-95.1, -24.1) 	-77.8 (-100.0, -50.6) 	
Discontinued study 	6 (54.5%) 	7 (70.0%) 	0 	13 (43.3%) 	54.5 (25.1, 84.0) 	70.0 (41.6, 98.4) 	
Other 	6 (54.5%) 	7 (70.0%) 	0 	13 (43.3%) 	54.5 (25.1, 84.0) 	70.0 (41.6, 98.4)